Skip to main content

Table 3 Effect of spinal cord B1R stimulation on tactile allodynia in STZ-diabetic rats

From: Key role for spinal dorsal horn microglial kinin B1receptor in early diabetic pain neuropathy

Tactile allodynia (g)

 

0 min

5 min

10 min

15 min

30 min

60 min

Control rats

      

Vehicle

9.7 ± 0.3

9.7 ± 0.3

9.3 ± 0.7

9.7 ± 0.3

9.7 ± 0.3

9.7 ± 0.3

DABK (9.6 nmol, i.t.)

9.7 ± 0.3

9.7 ± 0.3

9.3 ± 0.7

9.7 ± 0.3

9.7 ± 0.3

9.7 ± 0.3

SSR240612 (10 μg, i.t.) + DABK

10.7 ± 0.3

9.7 ± 0.3

9.3 ± 0.7

9.7 ± 0.3

9.7 ± 0.3

9.7 ± 1.3

FLU (1 nmol, i.t.) + DABK

9.7 ± 0.3

9.7 ± 0.3

9.3 ± 0.7

9.7 ± 0.3

9.7 ± 0.3

9.7 ± 0.3

Mino (10 mg/kg, i.p.) + DABK

9.7 ± 0.3

9.7 ± 0.3

9.3 ± 0.7

9.7 ± 0.3

9.7 ± 0.3

9.7 ± 0.3

Tactile allodynia (g)

 

0 min

5 min

10 min

15 min

30 min

60 min

STZ-treated rats

      

Vehicle

6.3 ± 0.3***

6.0 ± 0.5***

6.3 ± 0.3***

6.3 ± 0.3***

6.3 ± 0.3***

6.0 ± 0.5***

DABK (9.6 nmol, i.t.)

6.0 ± 0.5***

5.3 ± 0.4***

4.3 ± 0.3++ ***

5.3 ± 0.4***

6.0 ± 0.0***

5.7 ± 0.3***

SSR240612 (10 μg, i.t.) + DABK

9.3 ± 0.3+++

9.3 ± 0.0+++

9.3 ± 0.0+++

9.3 ± 0.3+++

9.7 ± 0.3+++

9.3 ± 0.0+++

FLU (1 nmol, i.t.) + DABK

9.7 ± 0.3+++

9.7 ± 0.3+++

9.7 ± 0.3+++

9.7 ± 0.3+++

9.3 ± 0.4+++

9.3 ± 0.4+++

Mino (10 mg/kg, i.p.) + DABK

9.7 ± 0.3+++

9.0 ± 0.4+++

9.3 ± 0.4+++

9.3 ± 0.4+++

8.7 ± 0.4+++

9.3 ± 0.4+++

  1. Time-course effect of a single intrathecal (i.t.) injection of the B1R agonist, des-Arg9-BK (DABK, 9.6 nmol), on the paw withdrawal threshold to tactile stimulation (g) in control and 4-day STZ-diabetic rats pre-treated, 3 h earlier, with either B1R antagonist (SSR240612), microglia inhibitors (minocycline, fluorocitrate) or vehicle. Data represent the mean ± S.E.M. of 4 to 12 rats in each group. Statistical comparison to vehicle in control (*) and STZ-treated rats (+) is indicated by ++P < 0.01; *** +++P < 0.001